Skip to main content
Equibles
AMGN logo

AMGN · Amgen Inc · Webcasts, Transcripts & Audio

Track AMGN — free

Use AMGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$439.26 -8.02 (-1.79%) At close · Oct 23
S&P 500 member Nasdaq-100 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$237.48B
Shares
540.63M
Volume · Oct 23 2.08M Avg daily vol (3M) 2.82M

Amgen Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Amgen Inc (AMGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-15
Amgen Inc (AMGN) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-06
Amgen Inc (AMGN) September 6, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-04-08
Amgen Inc (AMGN) Q2 2026 Earnings Call Transcript
Confident tone Repatha (PCSK9 / cardiovascular) Obesity / MariTide pipeline Six key growth drivers / portfolio breadth
Revenue
$10.05B
▲ 9.5% YoY
Diluted EPS
$4.37
▲ 64.9% YoY
Gross margin
72.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-03
Amgen Inc (AMGN) Q4 2025 Earnings Call Transcript
Positive tone Meritide obesity pipeline Growth drivers (Repatha, Evenity, TestSpire) Tavneos / ChemoCentryx FDA request for withdrawal
Revenue
$9.87B*
▲ 8.6% YoY
Gross margin
69.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Amgen Inc (AMGN) Q3 2025 Earnings Call Transcript
Confident tone Cardiovascular franchise (Repatha, Olpasiran) Rare diseases and UPLIZNA expansion Volume growth and broad portfolio momentum
Revenue
$9.56B
▲ 12.4% YoY
Diluted EPS
$5.93
▲ 13.6% YoY
Gross margin
67.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Amgen Inc (AMGN) Q2 2025 Earnings Call Transcript
Confident tone MariTide obesity program Oncology and BiTE platform General medicine portfolio (Repatha, EVENITY, Prolia)
Revenue
$9.18B
▲ 9.4% YoY
Diluted EPS
$2.65
▲ 92% YoY
Gross margin
67.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Amgen Inc (AMGN) Q1 2025 Earnings Call Transcript
Confident tone Obesity / MariTide Rare disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS) Cardiovascular / Repatha
Revenue
$8.15B
▲ 9.4% YoY
Diluted EPS
$3.20
Gross margin
63.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-04
Amgen Inc (AMGN) Q4 2024 Earnings Call Transcript
Confident tone Pipeline catalysts (MariTide, rocatinlimab, oncology) Repatha expansion Rare disease portfolio / TEPEZZA international
Revenue
$9.09B*
▲ 10.9% YoY
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Amgen Inc (AMGN) Q3 2024 Earnings Call Transcript
Confident tone Rare disease franchise (Horizon) MariTide (obesity/obesity-related pipeline) General medicine growth (Repatha, EVENITY, Prolia)
Revenue
$8.50B
▲ 23.2% YoY
Diluted EPS
$5.22
▲ 62.1% YoY
Gross margin
61.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Amgen Inc (AMGN) Q2 2024 Earnings Call Transcript
Confident tone MariTide / obesity pipeline Oncology launches and label expansions Pipeline breadth and 2024 milestones
Revenue
$8.39B
▲ 20.1% YoY
Diluted EPS
$1.38
▼ 46.3% YoY
Gross margin
61.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Amgen Inc (AMGN) Q1 2024 Earnings Call Transcript
Confident tone TEPEZZA safety/monitoring and subcutaneous development MariTide (obesity/obesity-related conditions/diabetes) Rare disease / Horizon integration
Revenue
$7.45B
▲ 22% YoY
Diluted EPS
$-0.21
▼ 104% YoY
Gross margin
57.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Amgen Inc (AMGN) Q4 2023 Earnings Call Transcript
Positive tone Horizon Acquisition / Rare Disease Pillar MariTide / Obesity Pipeline Volume Growth & Geographic Expansion
Revenue
$8.20B*
▲ 19.8% YoY
Gross margin
62.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Amgen Inc (AMGN) Q3 2023 Earnings Call Transcript
Revenue
$6.90B
▲ 3.8% YoY
Diluted EPS
$3.22
▼ 19.1% YoY
Gross margin
73.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Amgen Inc (AMGN) Q2 2023 Earnings Call Transcript
Revenue
$6.99B
▲ 5.9% YoY
Diluted EPS
$2.57
▲ 4.9% YoY
Gross margin
74.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Amgen Inc (AMGN) Q1 2023 Earnings Call Transcript
Revenue
$6.11B
▼ 2.1% YoY
Diluted EPS
$5.28
▲ 97% YoY
Gross margin
71.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-31
Amgen Inc (AMGN) Q4 2022 Earnings Call Transcript
Revenue
$6.84B*
▼ 0.1% YoY
Gross margin
74.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Amgen Inc (AMGN) Q3 2022 Earnings Call Transcript
Revenue
$6.65B
▼ 0.8% YoY
Diluted EPS
$3.98
▲ 20.2% YoY
Gross margin
76.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Amgen Inc (AMGN) Q2 2022 Earnings Call Transcript
Revenue
$6.59B
▲ 1% YoY
Diluted EPS
$2.45
▲ 202.5% YoY
Gross margin
77.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Amgen Inc (AMGN) Q1 2022 Earnings Call Transcript
Revenue
$6.24B
▲ 5.7% YoY
Diluted EPS
$2.68
▼ 5.3% YoY
Gross margin
75.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-07
Amgen Inc (AMGN) Q4 2021 Earnings Call Transcript
Revenue
$6.85B*
▲ 3.2% YoY
Gross margin
74.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Amgen Inc (AMGN) Q3 2021 Earnings Call Transcript
Revenue
$6.71B
▲ 4.4% YoY
Diluted EPS
$3.31
▼ 3.5% YoY
Gross margin
76.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Amgen Inc (AMGN) Q2 2021 Earnings Call Transcript
Revenue
$6.53B
▲ 5.2% YoY
Diluted EPS
$0.81
▼ 73.4% YoY
Gross margin
74.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-27
Amgen Inc (AMGN) Q1 2021 Earnings Call Transcript
Revenue
$5.90B
▼ 4.2% YoY
Diluted EPS
$2.83
▼ 7.8% YoY
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-02
Amgen Inc (AMGN) Q4 2020 Earnings Call Transcript
Revenue
$6.63B*
▲ 7.1% YoY
Diluted EPS
$2.76
▼ 3.2% YoY
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Amgen Inc (AMGN) Q3 2020 Earnings Call Transcript
Revenue
$6.42B
▲ 12% YoY
Diluted EPS
$3.43
▲ 4.9% YoY
Gross margin
70.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Amgen Inc (AMGN) Q2 2020 Earnings Call Transcript
Revenue
$6.21B
▲ 5.7% YoY
Diluted EPS
$3.05
▼ 14.6% YoY
Gross margin
71.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Amgen Inc (AMGN) Q1 2020 Earnings Call Transcript
Revenue
$6.16B
▲ 10.9% YoY
Diluted EPS
$3.07
▼ 3.5% YoY
Gross margin
71.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–27 of 27 webcasts
Key facts CIK 318154 CUSIP 031162100 13F (30d) 1090 filings 1064 filers Visit website Investor relations